SummaryNaloxone is a small molecule drug that acts as an antagonist at the μ opioid receptor, making it a potent tool in the treatment of opiate and drug overdose. The drug works by blocking the receptor site, reversing the effects of opioids on the central nervous system and restoring normal respiration. Originally developed by Endo Pharmaceuticals, naloxone was first approved for use in 1971. |
Drug Type Small molecule drug |
Synonyms Naloxone, Naloxone hydrochloride (JP17/USP), Naloxone hydrochloride dihydrate + [45] |
Target |
Action antagonists |
Mechanism μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 Apr 1971), |
RegulationFast Track (United States), Orphan Drug (European Union), Priority Review (United States) |
Molecular FormulaC19H22ClNO4 |
InChIKeyRGPDIGOSVORSAK-STHHAXOLSA-N |
CAS Registry357-08-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01340 | Naloxone hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Lymphoblastic Leukemia | Canada | 01 Feb 2025 | |
Opiate Overdose | United States | 13 Apr 1971 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid abuse | Preclinical | United States | - |
Phase 1/2 | 126 | (Naloxone) | ilwknsacad(wbcjkoxskl) = pkgzqeaymn qhdxfnoozr (mvfxziymkn, 2.15) View more | - | 20 Apr 2025 | ||
Placebo (Placebo) | ilwknsacad(wbcjkoxskl) = onbemerwmc qhdxfnoozr (mvfxziymkn, 1.99) View more | ||||||
Phase 1 | 10 | Placebo+Naloxone Hydrochloride (Pain Group) | mfawhajrdm(rhqbxltmgx) = bdjvqvcvtt inhntalrxj (pyqdajhllw, 1.17) View more | - | 26 Mar 2025 | ||
Placebo+Naloxone Hydrochloride (No Pain Group) | mfawhajrdm(rhqbxltmgx) = gulciqswdp inhntalrxj (pyqdajhllw, 0.92) View more | ||||||
Phase 4 | 53 | bypibzyfzv = jidzyfynri zekomnhalj (ypkabbsime, glbvndnlte - pfyhxteqan) View more | - | 01 Jul 2024 | |||
Phase 2 | 30 | (Naloxone) | xmudecxpfa(pwiobdbpyq) = yfbsevkfhc xanyhhwyhx (nrvefpiggc, 12) View more | - | 16 Apr 2024 | ||
placebo (Placebo) | xmudecxpfa(pwiobdbpyq) = dxmsemvhko xanyhhwyhx (nrvefpiggc, 13) View more | ||||||
Phase 1 | 21 | 1 dose at 0, 2.5, 5, and 7.5 minutes | txztrqbdvp(xxkmxlrkdd) = hjiovmbxzh mxrryudmxc (mlvsqtwboi ) | - | 23 Jan 2024 | ||
2 doses at 0 and 2.5 minutes | txztrqbdvp(xxkmxlrkdd) = fxggadrwbl mxrryudmxc (mlvsqtwboi ) | ||||||
Not Applicable | - | asmqredjng(xntobripdi) = csfhrzurnr vdzpajlmot (hmnrjaslfg ) | - | 01 Jan 2024 | |||
intranasal naloxone (Control period (2013-2017)) | asmqredjng(xntobripdi) = truutcfsbj vdzpajlmot (hmnrjaslfg ) | ||||||
Not Applicable | - | zikcleqafz(zvemxvqnvc) = xcnlvhdifg meaecqzssx (heirtxujxw ) View more | - | 20 Jun 2023 | |||
Placebo | zikcleqafz(zvemxvqnvc) = odlrzrekds meaecqzssx (heirtxujxw ) View more | ||||||
Phase 1 | 56 | nmgrcfyulq(sxocepambd) = nqzhqodwcm wxifuomzfm (etrcognxkm ) View more | Similar | 28 Jul 2022 | |||
nmgrcfyulq(sxocepambd) = ghxlxpxzpx wxifuomzfm (etrcognxkm ) View more | |||||||
Phase 1 | - | 21 | (A. Four Naloxone Nasal Spray Doses (1 Every 2.5 Min)) | anqwpmtezv(gioxlfzmbk) = prjbgkgtta tgaixglhtw (sxbiakwnzh, 70) View more | - | 15 Jul 2022 | |
(C. Two Naloxone Nasal Spray Doses (1 Every 2.5 Min)) | anqwpmtezv(gioxlfzmbk) = fjzcpljxkw tgaixglhtw (sxbiakwnzh, 159) View more | ||||||
Phase 2 | 41 | Placebo+Naloxone (Placebo, Then Naloxone) | ptlfflxivv(yulfzoyojc) = julcakaxpu ceiqfwanbx (gpqajvudbn, iivtdjsidm - qxcoumbydx) View more | - | 03 Nov 2021 | ||
Placebo+Naloxone (Naloxone, Then Placebo) | ptlfflxivv(yulfzoyojc) = gmkklmgozu ceiqfwanbx (gpqajvudbn, zmrautvetd - lwvuacxsil) View more |